New drug trial hopes to shrink Hard-to-Treat pancreatic tumors
NCT ID NCT07561463
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a drug called sacituzumab tirumotecan in 30 people with advanced pancreatic cancer that has worsened after at least one prior treatment. The drug is given by IV every two weeks. The main goal is to see if it can shrink tumors, and researchers will also track how long the effect lasts and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacituzumab tirumotecan (a drug given by IV every 2 weeks)
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced pancreatic cancer who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can zapping pancreatic tumors with heat before surgery boost Chemo's power?
- Can a radioactive tracer light up hidden tumors? a new trial aims to find out
- Breath of life: new test could sniff out gut cancers before they spread
- Scientists hunt for biomarkers to catch pancreatic cancer before it strikes
- New PET tracer aims to spot hidden cancer spread in the abdomen
- Experimental drug inavolisib targets Hard-to-Treat pancreatic cancer